Roivant Sciences Ltd. is a biopharmaceutical company that employs a unique, decentralized "Vant" business model to develop and commercialize innovative medicines and health technologies. Under this model, Roivant creates specialized subsidiary companies (Vants)—such as Immunovant and Priovant—each dedicated to specific therapeutic areas, drug candidates, or technology platforms. This structure is designed to align incentives, streamline research and development, and accelerate the path to market. The company's pipeline spans immunology, dermatology, and oncology, with late-stage candidates like brepocitinib for dermatomyositis and IMVT-1402 for IgG-mediated autoimmune diseases. Roivant also develops healthcare technologies, having previously launched Datavant and Genevant, which focuses on lipid nanoparticle (LNP) delivery platforms. The company actively manages its portfolio through strategic divestitures, such as the 2023 sale of Televant to Roche and the 2024 sale of its dermatology subsidiary Dermavant (maker of the psoriasis treatment VTAMA) to Organon. Headquartered in London with significant operations in the United States and Switzerland, Roivant aims to reduce inefficiencies in the drug development process by acquiring deprioritized assets from larger pharmaceutical firms and advancing them through its agile subsidiary network.
